Conduit Pharmaceuticals has recently signed a licensing agreement with AstraZeneca for multiple assets. This exclusive deal marks a significant milestone for Conduit Pharmaceuticals, as they continue to expand their portfolio of products. The partnership with AstraZeneca is expected to bring new opportunities for growth and development for both companies. This collaboration demonstrates the potential for Conduit Pharmaceuticals to make a positive impact in the pharmaceutical industry. Stay tuned for more updates on this exciting partnership.